Nephros Inc

Aktienanalyse zu Nephros Inc (NEPH)

$2.833

-0.236 (-8.32%)Zum Schluss

Loading chart…
Hoch
3.080
Eröffnung
3.080
Volumengewichteter Durchschnittskurs
2.88
Volumen
104.01K
Marktkap.
22.04M
Tief
2.720
Umsatz
299.30K
EV/EBITDA, TTM
5.64

Nephros, Inc. is a water technology company providing filtration solutions to the medical and commercial markets. The Company provides water filtration products and services, along with water-quality education. In the medical markets, it sells water filtration products. In the commercial market, it manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, heavy metals, chemical compounds, scale build-up in downstream equipment, and various other contaminants. Its products are marketed primarily to the food service, hospitality, convenience store, and healthcare markets. These commercial products are also marketed in medical markets as supplemental filtration to its medical filters. Its filters are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate.

www.nephros.com

KI-Analyse of Nephros Inc (NEPH)

Halten

Nephros Inc is currently not a strong buy due to its low RSI of 16.83, indicating oversold conditions, and a significant 40.36% year-to-date decline. While the company reported record revenue of $6 million in Q2 2026 and a net income increase of over 400% to approximately $1.2 million, the stock's recent performance has been poor, with a 10.63% drop over the last five days. The main risk is its high debt to equity ratio of 6.17%, which could impact financial stability.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Nephros Inc (NEPH) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -23.55.

Erwartetes KGV

Fair bewertet
5J-Durchschnitt P/E
-23.55
Aktuelles P/E
0.00
Überbewertet
118.86
Unterbewertet
-165.96

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
3.79
Aktuelles EV/EBITDA
5.64
Überbewertet
28.55
Unterbewertet
-20.97

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
1.85
Aktuelles P/S
1.31
Überbewertet
3.01
Unterbewertet
0.69

Alphio-AI-Kursszenarien für NEPH

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%NEPH

$3.45

Szenariopreis

B

Basis

Basis · 50%NEPH

$2.82

Szenariopreis

B

Bärisch

Bärisch · 25%NEPH

$2.02

Szenariopreis

Event-Zeitleiste

2026-08-06 (ET)

18:00:00

Nephros Reports Q2 Revenue of $6.02M

2026-02-13 (ET)

08:20:00

Nephros Enters Puerto Rican Market to Address Water Quality Needs

2025-12-11 (ET)

09:10:00

Nephros Launches Water Institute to Enhance Industry Education

2025-10-08 (ET)

09:11:53

Nephros Introduces New Filter for PFAS Removal

2024-10-24 (ET)

09:09:57

Nephros launches HydraGuard 20" UltraFilter

News

NEPH FAQ – beantwortet von Alphio AI

Nephros, Inc. is a water technology company providing filtration solutions to the medical and commercial markets. The Company provides water filtration products and services, along with water-quality education. In the medical markets, it sells water filtration products. In the commercial market, it manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, heavy metals, chemical compounds, scale build-up in downstream equipment, and various other contaminants. Its products are marketed primarily to the food service, hospitality, convenience store, and healthcare markets. These commercial products are also marketed in medical markets as supplemental filtration to its medical filters. Its filters are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. It operates in the Industrials sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Nephros Inc is currently not a strong buy due to its low RSI of 16.83, indicating oversold conditions, and a significant 40.36% year-to-date decline. While the company reported record revenue of $6 million in Q2 2026 and a net income increase of over 400% to approximately $1.2 million, the stock's recent performance has been poor, with a 10.63% drop over the last five days. The main risk is its high debt to equity ratio of 6.17%, which could impact financial stability.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Ähnliche Artikel

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln